Last reviewed · How we verify

Pantoprazole 40mg

Universitaire Ziekenhuizen KU Leuven · FDA-approved active Small molecule Quality 2/100

Pantoprazole 40mg, marketed by Universitaire Ziekenhuizen KU Leuven, is a well-established proton pump inhibitor in the gastrointestinal therapeutic area. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in generic competition following the patent expiry.

At a glance

Generic namePantoprazole 40mg
Also known asPantomed, Protonix, Apo-Pantoprazole, Pantoprazole, Pantorc
SponsorUniversitaire Ziekenhuizen KU Leuven
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: